Bioregenx (BRGX) Cash from Operations (2022 - 2025)
Bioregenx has reported Cash from Operations over the past 4 years, most recently at 69636.0 for Q4 2025.
- For Q4 2025, Cash from Operations rose 712.94% year-over-year to 69636.0; the TTM value through Dec 2025 reached 38972.0, up 112.02%, while the annual FY2025 figure was 38972.0, 112.02% up from the prior year.
- Cash from Operations for Q4 2025 was 69636.0 at Bioregenx, up from 71564.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 69636.0 in Q4 2025 and troughed at 649161.0 in Q2 2023.
- A 4-year average of 116554.44 and a median of 32153.0 in 2022 define the central range for Cash from Operations.
- Biggest five-year swings in Cash from Operations: tumbled 5528.46% in 2023 and later surged 712.94% in 2025.
- Year by year, Cash from Operations stood at 4364.0 in 2022, then tumbled by 5528.46% to 245626.0 in 2023, then soared by 95.37% to 11361.0 in 2024, then surged by 712.94% to 69636.0 in 2025.
- Business Quant data shows Cash from Operations for BRGX at 69636.0 in Q4 2025, 71564.0 in Q3 2025, and 3205.0 in Q2 2025.